Member Info for matarakz

Proaxis was already breakeven last year. Hopefully this year it is profitable and I’m expecting 200% growth this year.

The good things are Glycotest and Proaxis products are patented. Unlike other tests which are generic.

Please follow Baz at twitter. He is very knowledgeable about the company. Gl

Indeed, hopefully the wall at £3 would collapse today . Gl

Well said!

I have a great feeling that the iron wall at £3 would collapse today imho. Fundamentals are getting stronger and patient investors are rewarded soon here.

Patience is the key here. It is the patient investors who are rewarded . I have 300,000 shares here and i trust my own research. All of the company’s portfolio are doing great. Glycotest, Proaxis, Pds Bio. To the investors please visit their websites . My target price is £1. Imho Dyor

A healthy consolidation ! Patient investors are rewarded here imho.

The results of the preclinical for Pds4 is due this week imho. It is funded by the Brazilian government for phase 1 Imho.

$16 billion was allocated for Covid 19 testing by US congress. Novacyt is growing in America. Hold and buy at dip. Fundamentals and Science would prevail imho. Gl

This is the real deal . Novacyt always delivers. Fundamentals are getting stronger.

For investors here, please limil your post here . We need stability here like Batm. You are only attracting day traders. Ggg and VanV only post few now.

I appreciate your hard-work about the Financial analysis update but the problem is other investors would see this as a speculative buy. Why can’ t we just have a conservative revenue projection.
Year end revenue more than £200 million
Year end Profit after tax more than £100 million
Year end Sales/Order more than £300 million
This figure is excellent.

Paris at €3. Recovery is underway

Well said,! U’ve already contributed a lot in here. Less post and it would bring stability here like Batm.

Please remember -No other Aim companies like Novacyt. Dilutions and issue of equities are common in Aim. That is big factor why I’m a long term investor here. Gdr, Avacta, , Odx in few months time you gonna expect that they would raise money again. Imho

Comparing Novacyt to Batm and Ekf , Novacyt is at much better position in terms of revenue, growth and innovation. Still very undervalued. No debt and no issue of equities. Imho

Please let us educate ourselves
Revenue , Sales/order , Production are totally different.
Rns was excellent and the 2nd half revenue would be better. We have to be thankful , the company is debt free and no issue of equities.Imho , fundamentals are getting stronger.

That was an excellent rns!

I’m tempting to sell my EUA and top up here. This is still very undervalued.